DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Intervention: olopatadine 0.2% (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Stella Robertson, Study Director, Affiliation: Study Director


The purpose of this study is to demonstrate that Olopatadine 0. 2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Clinical Details

Official title: A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Daily signs and symptoms scores during the 14 days of peak pollen

Secondary outcome: Patients with daily signs and symptoms scores of zero during the 14 days of peak pollen


Minimum age: 10 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass

antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model Exclusion Criteria:

- Under 10 years of age

Locations and Contacts

Alcon Research, Ltd., Fort Worth, Texas 76134, United States
Additional Information

Starting date: August 2006
Last updated: June 11, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017